UA-MHC HLA-A*0201/SLLMWITQC NY-ESO-1 tetramer-PE labeled in the detection of antigen-specific T cells
Tumor-associated antigen-specific CD8+ T cells play a central role in tumor immune surveillance. Accurate identification and quantitative analysis of tumor antigen-specific T cells are key technical steps in elucidating anti-tumor immune mechanisms, evaluating immunotherapy efficacy, and monitoring disease progression.
- Recent Advances
- Product Information
I. Clinical Research Value of Antigen-Specific T Cell Detection
Tumor-associated antigen-specific CD8+ T cells play a central role in tumor immune surveillance. Accurate identification and quantitative analysis of tumor antigen-specific T cells are key technical steps in deciphering anti-tumor immune mechanisms, evaluating immunotherapy efficacy, and monitoring disease progression. Traditional functional detection methods such as enzyme-linked immunospot (ELISPOT) assay and intracellular cytokine staining (ICS) can reflect the functional state of T cells but cannot directly determine the frequency and phenotype of antigen-specific T cells. The establishment of major histocompatibility complex (MHC) tetramer technology has provided a powerful tool for the direct visualization and quantitative analysis of human tumor antigen-specific T cells, advancing tumor immunology research.
II. Core Principle of MHC Tetramer Technology
The principle of MHC tetramer technology is based on the specific recognition between the T cell receptor (TCR) and the MHC-antigen peptide complex. Biotinylated monomeric MHC-antigen peptide complexes are mixed with fluorescently labeled streptavidin in an optimized ratio. The four biotin-binding sites of streptavidin can simultaneously bind four MHC monomers, forming a stable tetramer structure. This tetramer structure significantly enhances the binding affinity to antigen-specific TCRs, enabling stable labeling of antigen-specific CD8+ T cells. Combined with flow cytometry, labeled cells can be precisely characterized and quantified. Additionally, by co-staining with other surface markers, the phenotypic characteristics, differentiation status, and functional subsets of antigen-specific T cells can be deeply investigated. This technology has been widely applied in the detection of antigen-specific T cells in human peripheral blood, tumor tissues, and lymphoid organs.
III. Construction and Characteristics of HLA-A*0201/SLLMWITQC NY-ESO-1 Tetramer
The HLA-A*0201/SLLMWITQC NY-ESO-1 tetramer is a specific detection tool assembled from the human HLA-A*0201 MHC class I molecule and the SLLMWITQC peptide derived from the cancer-testis antigen NY-ESO-1. This tetramer is labeled with PE fluorescence, offering high sensitivity, high specificity, and excellent photostability. PE fluorophore has high quantum yield and strong resistance to photobleaching, making it suitable for multicolor flow cytometry analysis of human samples. The NY-ESO-1 antigen is expressed in various tumor types, including melanoma, sarcoma, lung cancer, esophageal cancer, and ovarian cancer, while its expression in normal tissues is limited to testicular germ cells, making it an ideal target for tumor immunotherapy. This tetramer can specifically recognize CD8+ T cells with TCRs targeting the NY-ESO-1 antigen peptide and is widely used in the detection and analysis of antigen-specific CD8+ T cells in human tumor immunology research.
IV. Applications in Tumor Immune Monitoring
The HLA-A*0201/SLLMWITQC NY-ESO-1 tetramer plays a critical role in monitoring the immune status of tumor patients. Using this tetramer, researchers can detect the frequency of NY-ESO-1-specific CD8+ T cells in peripheral blood mononuclear cells (PBMCs) and analyze its correlation with tumor burden, disease stage, and prognosis. In tumor tissues, this tetramer can be used to detect the proportion and distribution of NY-ESO-1-specific T cells among tumor-infiltrating lymphocytes (TILs). By co-staining with immune checkpoint molecules such as PD-1, CTLA-4, and TIM-3, the functional exhaustion state of antigen-specific T cells in the tumor microenvironment can be assessed, providing important data for uncovering tumor immune evasion mechanisms. This method offers objective indicators for immune stratification and prognosis prediction in tumor patients.
V. Applications in Immunotherapy Efficacy Evaluation
Immune checkpoint blockade therapy and adoptive T cell therapy (e.g., TCR-T) have shown significant progress in various tumor types. The HLA-A*0201/SLLMWITQC NY-ESO-1 tetramer provides a direct detection tool for evaluating the immune effects of these therapeutic strategies. In patients receiving immunotherapy, this tetramer can be used to dynamically monitor changes in the frequency of NY-ESO-1-specific CD8+ T cells and assess the extent of T cell expansion induced by treatment. By co-staining with memory markers such as CD45RO, CD62L, and CCR7, the differentiation status of effector memory T cells and central memory T cells can be further analyzed. Co-staining with the proliferation marker Ki-67 can assess the in vivo proliferative activity of antigen-specific T cells. The correlation analysis of these parameter changes with clinical efficacy provides key data support for understanding treatment mechanisms and optimizing therapeutic strategies.
VI. Applications in Tumor Vaccine Development
The core goal of tumor vaccine development is to induce durable tumor antigen-specific T cell immune responses. The HLA-A*0201/SLLMWITQC NY-ESO-1 tetramer provides a standardized tool for evaluating the immunogenicity of tumor vaccines. After vaccination with NY-ESO-1 antigen-containing candidate vaccines, this tetramer can be used to detect the frequency of SLLMWITQC-specific CD8+ T cells in peripheral blood, assessing the strength and durability of the T cell response induced by the vaccine. By comparing the antigen-specific T cell responses induced by different vaccine vectors, adjuvants, and immunization regimens, the optimal immunization strategy can be screened, providing immunological data support for the clinical translation of tumor vaccines. This method offers high sensitivity, enabling the detection of low-frequency antigen-specific T cells, and is suitable for immune monitoring in early-stage clinical research.
VII. Which Manufacturers Provide UA-MHC HLA-A*0201/SLLMWITQC NY-ESO-1 Tetramer-PE?
Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed the "UA-MHC HLA-A*0201/SLLMWITQC NY-ESO-1 Tetramer-PE Labelled", a high-performance MHC tetramer reagent specifically designed for the identification and sorting of antigen-specific CD8+ T cells. This product is based on the human HLA-A*0201 MHC class I molecule complexed with the SLLMWITQC antigen peptide derived from the NY-ESO-1 tumor antigen and labeled with PE fluorescence. It aims to accurately and efficiently identify and quantify antigen-specific CD8+ T cells, providing a stable and reliable standardized tool for tumor immunotherapy, cancer vaccine development, immune monitoring, and other fields.
| Core Advantages of the Product |
|---|
| High Specificity and Accurate Identification: The product employs the HLA-A*0201 MHC class I molecule and the NY-ESO-1 tumor antigen peptide SLLMWITQC complex, which has undergone rigorous validation and folds correctly into its native conformation, ensuring high-affinity binding to antigen-specific T cell receptors. The optimized tetramerization technology forms a stable multimeric structure, significantly enhancing the staining signal for antigen-specific CD8+ T cells and enabling accurate identification and quantitative analysis. |
| High Purity and Intact Biological Activity: Leveraging an internationally leading MHC tetramer technology platform and a highly standardized production process, the product undergoes multi-dimensional quality control validation to ensure >95% high purity, correct spatial conformation, and intact biological activity. The PE labeling process is optimized to maximize labeling efficiency while preserving the specific binding capability of the MHC tetramer. |
| Excellent Batch-to-Batch Consistency and Stability: Strict quality control is implemented throughout the entire process, from protein expression and peptide folding to fluorescent labeling, ensuring each batch of products exhibits stable binding activity, consistent fluorescence intensity, and excellent long-term stability. This provides solid and reliable quality assurance for long-term and continuous antigen-specific T cell research. |
| Ready-to-Use Flexible Experimental Protocols: The product is provided in a ready-to-use liquid format and can be directly applied to flow cytometry staining analysis. The optimized formulation ensures low background and high signal-to-noise ratio staining effects, making it suitable for various application needs, including NY-ESO-1-specific CD8+ T cell identification, sorting, frequency analysis, and immune function evaluation. |
| Comprehensive Solutions and Professional Support: We provide fully validated standard experimental protocols, typical staining data, and detailed result interpretation guidelines to help you quickly establish stable and reproducible MHC tetramer staining workflows. The Nanjing UA-Bio professional technical team offers comprehensive and professional technical consultation and support for your research design, experimental optimization, and data analysis. |
Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or specific application inquiries regarding the "UA-MHC HLA-A*0201/SLLMWITQC NY-ESO-1 Tetramer-PE Labelled" (Catalog No.: UA089018), please feel free to contact us.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Business license (three certificates in one) 